Syngene concludes acquisition of Emergent BioSolutions’ biologics manufacturing facility
The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Syngene International
Syngene International appoints Peter Bains as CEO Designate
Jonathan Hunt steps down as MD & CEO; Board announces leadership transition
Syngene announces winners of the annual science quiz ‘Synquizitive’
The programme featured a curriculum-aligned question bank incorporating real-world scenarios with the aim of fostering critical…
Passing of Biosecure Act a positive development
Jonathan Hunt MD and CEO, Syngene International analyses that though the change in the Biosecure Act around the timeline of…
Syngene announces 2nd year of STEM scholarship and mentorship program for women in collaboration…
30 women from tier 2 and 3 institutions have been selected for the second cohort of the program
Syngene biologics facility to be operational for US, European customers from mid-year
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million…
Syngene concludes acquisition of biologics facility from Stelis Biopharma
The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted…
Panbela announces issuance of key patent in Japan
The patent, developed in collaboration with Syngene International, is for claims of a novel process for the production of SBP-101
Syngene reports Q2 results
Revenue from operations up 26 per cent to Rs 768 crore, PAT increased 11 per cent to Rs 102 crore
Syngene reports full year revenue from operations up 19 per cent to Rs 2,604 crores
Revenue from operations up 15 per cent to Rs 758 crores in fourth quarter